- Meeting abstract
- Open Access
- Published:
Identification and characterization of small molecular NPR-B receptor antagonists
BMC Pharmacology and Toxicology volume 16, Article number: A70 (2015)
Background
Natriuretic peptides increase in heart failure. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) activate the natriuretic peptide receptor (NPR)-A and C-type natriuretic peptide (CNP) the NPR-B, causing production of cyclic 3’,5’-guanosine monophosphate (cGMP). Our group has previously shown that CNP potentiates β1-adrenoceptor-mediated inotropic response by increasing cAMP levels. This is explained by a crosstalk between cGMP and cAMP, where cGMP produced by NPR-B inhibits phosphodiesterase (PDE) 3 from degrading cAMP. Increased β1-adrenoceptor signalling is harmful in heart failure which is the basis for use of β-blockers in heart failure therapy. Further, PDE3 inhibition has been associated with increased mortality in heart failure. Thus, an NPR-B antagonist could eliminate the unwanted effects due to PDE3 inhibition and increased β1-adrenoceptor signalling by CNP. There are no selective NPR-B antagonists available, and our aim is to identify and characterize novel non-peptide small molecular selective NPR-B antagonists for potential use in heart failure therapy.
Methods
Small molecular compounds were screened for activity and selectivity towards NPR-A and NPR-B, using a cGMP assay based on AlphaScreen technology. Based on this technology, we can identify compounds that interfere with BNP- and CNP-stimulated cGMP production through the NPR-A and NPR-B receptor, respectively. Antagonism properties can also be characterized.
Results and Conclusion
Potential NPR-B antagonists were identified by high throughput screening of about 20,000 compounds. Hits were tested against the NPR-A to determine selectivity, and characterized as non-competitive and reversible inhibitors of NPR-B response in HEK293 cells, displaying properties of negative allosteric modulators [1]. Information on structure and activity relationship (SAR), was collected and over 50 new compounds, clustered in five different groups of chemically related compounds, were designed in silicoand were tested for activity and selectivity towards NPR-A and NPR-B. From this testing, three out of five groups were found interesting. The ligands with the best antagonistic property from each of the 3 groups were used to select 60 more compounds by in silicodesign for further testing.
References
- 1.
Bach T, Bergholtz S, Riise J, Qvigstad E, Skomedal T, Osnes JB, et al: Identification of small molecule NPR-B antagonists by high throughput screening - potential use in heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2014, 387 (1): 5-14. 10.1007/s00210-013-0940-6.
Author information
Rights and permissions
About this article
Cite this article
Andresen, H., Moltzau, L.R., Fagerheim, S. et al. Identification and characterization of small molecular NPR-B receptor antagonists. BMC Pharmacol Toxicol 16, A70 (2015). https://doi.org/10.1186/2050-6511-16-S1-A70
Published:
Keywords
- Natriuretic Peptide
- Brain Natriuretic Peptide
- Atrial Natriuretic Peptide
- PDE3 Inhibition
- Allosteric Modulator
